Skip to content

Acceptance of the CP950 Sound Processor

Acceptance of the CP950 Sound Processor With Experienced CP810/CP910/CP920 BTE Sound Processor Users

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03613909
Enrollment
23
Registered
2018-08-03
Start date
2015-11-30
Completion date
2016-11-30
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Sensorineural

Brief summary

Acceptance of CP950 sound processor with experienced CP810/CP910/CP920 BTE sound processor users.

Interventions

DEVICECP950 OTE Sound processor

CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor

Sponsors

Cochlear
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Repeated measures, single-subject experiment. Each subject received the same treatment.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Eighteen years of age or older 2. At least 6 months experience with a Nucleus 24 series or later implant in at least one implanted ear 3. At least 3 months experience with the CP810,CP920 or CP910 sound processor 4. Native speaker in the language used to assess speech perception performance 5. Willingness to participate in and to comply with all requirements of the protocol 6. Able to score 30% or more at +15 SNR with CI alone

Exclusion criteria

1. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device 2. Additional disabilities that would prevent participation in evaluations 3. Nucleus 22 Implant

Design outcomes

Primary

MeasureTime frameDescription
Acceptability Ratings for the CP950 Sound Processor Compared to Subjects' Own Processors, Summarized by the Overall Hearing Performance Score.14 daysEach subject used the Investigational device (CP950) for take home use to obtain subjective ratings. During the take home use, A subjective questionnaire was asked them to recall and rate how their hearing performance with the Investigational device CP950 OTE processor compared to their hearing performance with their own CP810, CP910 or CP920 BTE processor. Likert scale was used for each rating in the questionnaire for at home usage ( with the values ranging from) : 1 = much worse; 2 = somewhat worse; 3 = No difference; 4 = somewhat better; 5 = much better.

Secondary

MeasureTime frameDescription
Speech Reception Threshold (SNR50) for Sentence Testing in Noise With CP950 Sound Processor .in booth testing 1 day.Signal to noise ratio (measured in decibels) providing 50% speech intelligibility for sentences presented in noise to evaluate the benefit from microphone directionality with the CP950 OTE (Off the ear) sound processor.
Percentage of Correct Words Scored With Sentences in Noise With the CP950 Sound ProcessorIn booth testing 1 dayTwo lists of twenty sentences presented from front speaker with 4 Talker babble noise presented from rear-half speakers. Higher the percentage of correct words means better outcome.

Participant flow

Pre-assignment details

Protocol stated up to 25 number of participants. 23 were enrolled, with 3 electing to withdraw from the study before completion.

Participants by arm

ArmCount
All Participants
All participants enrolled in the study
23
Total23

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
7 Participants
Age, Categorical
Between 18 and 65 years
16 Participants
Age, Continuous57 years
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Australia
23 participants
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
19 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Acceptability Ratings for the CP950 Sound Processor Compared to Subjects' Own Processors, Summarized by the Overall Hearing Performance Score.

Each subject used the Investigational device (CP950) for take home use to obtain subjective ratings. During the take home use, A subjective questionnaire was asked them to recall and rate how their hearing performance with the Investigational device CP950 OTE processor compared to their hearing performance with their own CP810, CP910 or CP920 BTE processor. Likert scale was used for each rating in the questionnaire for at home usage ( with the values ranging from) : 1 = much worse; 2 = somewhat worse; 3 = No difference; 4 = somewhat better; 5 = much better.

Time frame: 14 days

ArmMeasureValue (MEAN)
All ParticipantsAcceptability Ratings for the CP950 Sound Processor Compared to Subjects' Own Processors, Summarized by the Overall Hearing Performance Score.3.6 Units on a likert scale
Secondary

Percentage of Correct Words Scored With Sentences in Noise With the CP950 Sound Processor

Two lists of twenty sentences presented from front speaker with 4 Talker babble noise presented from rear-half speakers. Higher the percentage of correct words means better outcome.

Time frame: In booth testing 1 day

ArmMeasureValue (MEAN)Dispersion
All ParticipantsPercentage of Correct Words Scored With Sentences in Noise With the CP950 Sound Processor49.82 percentage of correct words.Standard Deviation 3.9
Secondary

Speech Reception Threshold (SNR50) for Sentence Testing in Noise With CP950 Sound Processor .

Signal to noise ratio (measured in decibels) providing 50% speech intelligibility for sentences presented in noise to evaluate the benefit from microphone directionality with the CP950 OTE (Off the ear) sound processor.

Time frame: in booth testing 1 day.

ArmMeasureValue (MEAN)Dispersion
All ParticipantsSpeech Reception Threshold (SNR50) for Sentence Testing in Noise With CP950 Sound Processor .4 deciblesStandard Error 0.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026